Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494797 | 1.00 | ITGA4 (0.36) | ITGA4ITGB7MAPKAPK2IDO1GSK3B | |
| SCHEMBL5493523 | 0.89 | MAPKAPK2 (0.32) | MAPKAPK2IDO1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5493756 | 0.86 | GSK3B (0.33) | ITGA4ITGB7MAPKAPK2GSK3BDYRK1A | |
| SCHEMBL5492776 | 0.78 | ITGA4 (0.36) | ITGA4ITGB7MAPKAPK2IDO1 | |
| SCHEMBL5495034 | 0.77 | CA1 (0.40) | ITGA4ITGB7 | |
| SCHEMBL6066213 | 0.73 | TDP1 (0.36) | ITGA4ITGB7MAPKAPK2IDO1MEN1 | |
| SCHEMBL14819924 | 0.72 | ALDH1A1 (0.43) | GSK3BDYRK1AMEN1GLAKMT2A | |
| SCHEMBL5494835 | 0.72 | ACSS2 (0.36) | MAPKAPK2IDO1MEN1KMT2A | |
| SCHEMBL5493411 | 0.71 | RAB9A (0.31) | GSK3BDYRK1AMEN1GLAKMT2A | |
| SCHEMBL5493413 | 0.71 | RAB9A (0.31) | GSK3BDYRK1AMEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | ITGA4 3736/4885ITGB7 3000/4885MAPKAPK2 4584/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | ITGA4 3512/4885ITGB7 3253/4885MAPKAPK2 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.